FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223946478> ?p ?o ?g. }

• W4223946478 endingPage "784" @default.
• W4223946478 startingPage "778" @default.
• W4223946478 abstract "Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC may not be necessary.In this exploratory phase 2 study, mCRPC patients were randomized with a 1:1 ratio to receive either continued ADT plus AA + P (Arm A) or AA + P alone (Arm B). The primary endpoint was the rate of radiographic progression-free survival (rPFS) at month 12. Secondary endpoints included PSA-response rate, objective response, time to PSA progression and safety.A total of 68 patients were equally randomized between the two study arms. Median testosterone-levels remained below castrate-levels throughout treatment in all patients. According to the intention-to-treat analysis the rPFS rate was 0.84 in Arm A and 0.89 in Arm B. Moderate and severe treatment-emergent adverse events were reported for 72% of the patients in Arm A and for 85% of the patients in Arm B.AA + P treatment without ADT may be effective in mCRPC patients and ADT may not be necessary in patients receiving AA + P." @default.
• W4223946478 created "2022-04-19" @default.
• W4223946478 creator A5006530825 @default.
• W4223946478 creator A5009528133 @default.
• W4223946478 creator A5014528601 @default.
• W4223946478 creator A5016485880 @default.
• W4223946478 creator A5019298885 @default.
• W4223946478 creator A5024024391 @default.
• W4223946478 creator A5030641545 @default.
• W4223946478 creator A5049015849 @default.
• W4223946478 creator A5051748286 @default.
• W4223946478 creator A5055353385 @default.
• W4223946478 creator A5065099159 @default.
• W4223946478 creator A5066483373 @default.
• W4223946478 creator A5066534204 @default.
• W4223946478 creator A5067456208 @default.
• W4223946478 creator A5067940404 @default.
• W4223946478 creator A5068423096 @default.
• W4223946478 creator A5071196966 @default.
• W4223946478 creator A5079528891 @default.
• W4223946478 creator A5084974200 @default.
• W4223946478 creator A5085073457 @default.
• W4223946478 creator A5091890183 @default.
• W4223946478 date "2022-04-16" @default.
• W4223946478 modified "2023-10-15" @default.
• W4223946478 title "LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial" @default.
• W4223946478 cites W1997042762 @default.
• W4223946478 cites W2028798336 @default.
• W4223946478 cites W2035259770 @default.
• W4223946478 cites W2055346449 @default.
• W4223946478 cites W2070899129 @default.
• W4223946478 cites W2072875955 @default.
• W4223946478 cites W2101606728 @default.
• W4223946478 cites W2110534364 @default.
• W4223946478 cites W2113569308 @default.
• W4223946478 cites W2132986013 @default.
• W4223946478 cites W2137467802 @default.
• W4223946478 cites W2140144458 @default.
• W4223946478 cites W2171041379 @default.
• W4223946478 cites W2511755939 @default.
• W4223946478 cites W2559686304 @default.
• W4223946478 cites W2620798309 @default.
• W4223946478 cites W2763592002 @default.
• W4223946478 cites W2772636479 @default.
• W4223946478 cites W2775990182 @default.
• W4223946478 cites W2937483840 @default.
• W4223946478 cites W2938589827 @default.
• W4223946478 cites W2947586999 @default.
• W4223946478 doi "https://doi.org/10.1038/s41391-022-00533-6" @default.
• W4223946478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35430584" @default.
• W4223946478 hasPublicationYear "2022" @default.
• W4223946478 type Work @default.
• W4223946478 citedByCount "6" @default.
• W4223946478 countsByYear W42239464782022 @default.
• W4223946478 countsByYear W42239464782023 @default.
• W4223946478 crossrefType "journal-article" @default.
• W4223946478 hasAuthorship W4223946478A5006530825 @default.
• W4223946478 hasAuthorship W4223946478A5009528133 @default.
• W4223946478 hasAuthorship W4223946478A5014528601 @default.
• W4223946478 hasAuthorship W4223946478A5016485880 @default.
• W4223946478 hasAuthorship W4223946478A5019298885 @default.
• W4223946478 hasAuthorship W4223946478A5024024391 @default.
• W4223946478 hasAuthorship W4223946478A5030641545 @default.
• W4223946478 hasAuthorship W4223946478A5049015849 @default.
• W4223946478 hasAuthorship W4223946478A5051748286 @default.
• W4223946478 hasAuthorship W4223946478A5055353385 @default.
• W4223946478 hasAuthorship W4223946478A5065099159 @default.
• W4223946478 hasAuthorship W4223946478A5066483373 @default.
• W4223946478 hasAuthorship W4223946478A5066534204 @default.
• W4223946478 hasAuthorship W4223946478A5067456208 @default.
• W4223946478 hasAuthorship W4223946478A5067940404 @default.
• W4223946478 hasAuthorship W4223946478A5068423096 @default.
• W4223946478 hasAuthorship W4223946478A5071196966 @default.
• W4223946478 hasAuthorship W4223946478A5079528891 @default.
• W4223946478 hasAuthorship W4223946478A5084974200 @default.
• W4223946478 hasAuthorship W4223946478A5085073457 @default.
• W4223946478 hasAuthorship W4223946478A5091890183 @default.
• W4223946478 hasBestOaLocation W42239464781 @default.
• W4223946478 hasConcept C121608353 @default.
• W4223946478 hasConcept C126322002 @default.
• W4223946478 hasConcept C126894567 @default.
• W4223946478 hasConcept C143998085 @default.
• W4223946478 hasConcept C168563851 @default.
• W4223946478 hasConcept C197934379 @default.
• W4223946478 hasConcept C203092338 @default.
• W4223946478 hasConcept C2775832370 @default.
• W4223946478 hasConcept C2777899217 @default.
• W4223946478 hasConcept C2778720950 @default.
• W4223946478 hasConcept C2780192828 @default.
• W4223946478 hasConcept C71924100 @default.
• W4223946478 hasConceptScore W4223946478C121608353 @default.
• W4223946478 hasConceptScore W4223946478C126322002 @default.
• W4223946478 hasConceptScore W4223946478C126894567 @default.
• W4223946478 hasConceptScore W4223946478C143998085 @default.
• W4223946478 hasConceptScore W4223946478C168563851 @default.
• W4223946478 hasConceptScore W4223946478C197934379 @default.
• W4223946478 hasConceptScore W4223946478C203092338 @default.
• W4223946478 hasConceptScore W4223946478C2775832370 @default.

• next